Brought to you by 
Novartis licenses Paratek's PTK0796 antibiotic; terminated
Oct 2009
Executive Summary
Novartis has licensed exclusive global rights to Paratek Pharmaceuticals' (infectious disease therapeutics) PTK0796, a first-in-class IV broad-spectrum aminomethylcycline antibiotic in Phase III.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis licenses Paratek's PTK0796 antibiotic; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice